Compare SPCX & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCX | JNJ |
|---|---|---|
| Founded | N/A | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7T | 542.4B |
| IPO Year | 2026 | 2003 |
| Metric | SPCX | JNJ |
|---|---|---|
| Price | $137.96 | $273.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $238.20 |
| AVG Volume (30 Days) | ★ 103.3M | 6.6M |
| Earning Date | N/A | 04-14-2026 |
| Dividend Yield | N/A | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 4.41 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | N/A | $7.43 |
| P/E Ratio | ★ N/A | $61.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $104.83 | $173.33 |
| 52 Week High | $176.75 | $276.47 |
| Indicator | SPCX | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 61.45 |
| Support Level | $130.39 | $247.97 |
| Resistance Level | $149.80 | $274.90 |
| Average True Range (ATR) | 8.79 | 4.89 |
| MACD | 1.08 | 0.73 |
| Stochastic Oscillator | 69.76 | 74.94 |
Founded in 2002 and commonly known as SpaceX, the Space Exploration Technologies Corporation designs, manufactures, and operates a family of reusable rockets to launch various payloads into Earth orbit for government and commercial customers. Starting in 2019, the company began launching a constellation of its own communication satellites to provide mobile broadband and wireless services under the Starlink brand. In early 2026, the company acquired xAI from its founder, Elon Musk, which operates a large language artificial intelligence model named Grok, a gigawatt-scale data center called Colossus, and the social media network X.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.